N,N'-Diisobutyl-formamidin | 2303-92-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N'-Diisobutyl-formamidin
• 英文别名: N,N'-bis(2-methylpropyl)methanimidamide
• CAS: 2303-92-6
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: PRAMAMHZHDOFPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  在 异丁胺 作用下， 以 四氢呋喃 为溶剂， 生成 N,N'-Diisobutyl-formamidin
  参考文献：
  名称：

  Jentzsch,W., Chemische Berichte, 1964, vol. 97, p. 2755 - 2762

  摘要：

  DOI：

文献信息

• [EN] HIGHLY SELECTIVE ANTI-CANCER AGENTS TARGETING NON-SMALL CELL LUNG CANCER AND OTHER FORMS OF CANCER<br/>[FR] AGENTS ANTICANCÉREUX HAUTEMENT SÉLECTIFS CIBLANT LE CANCER DE POUMON NON À PETITES CELLULES ET D'AUTRES FORMES DE CANCER
  申请人：UNIV TOLEDO

  公开号：WO2014116594A1

  公开（公告）日：2014-07-31

  Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.

  本文描述了2-甲基-3-(2-乙炔基噻唑-4-基)环戊-2-烯醇及其相应的酮3-(2-乙炔基噻唑-4-基)-2-甲基环戊-2-烯酮的类似物，这些类似物在噻唑环的2位具有末端炔基团。这些类似药物分子被称为CETZOLE化合物，可用于治疗非小细胞肺癌和其他形式的癌症。还公开了制备和使用这些化合物的方法、治疗各种疾病的方法、药物组合物和试剂盒。
• Reagents for the Improved Synthesis of Isoguanosine Containing Oligonucleotides
  申请人：Prudent James R.

  公开号：US20080207890A1

  公开（公告）日：2008-08-28

  The present invention provides the combination of the O-2 diphenylcarbamoyl (“DPC”) and N-6 dimethy-laminomethylidene (“DMF”) protecting groups for isoguanosine nucleosides that can be utilized in oligonucleotide synthesis.

  本发明提供了O-2二苯基氨甲酰（“DPC”）和N-6二甲基氨甲亚甲基（“DMF”）保护基的组合，用于异鸟苷核苷类，在寡核苷酸合成中可利用。
• Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
  申请人：——

  公开号：US20030170680A1

  公开（公告）日：2003-09-11

  Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.

  本发明揭示了一种新型寡聚物，与仅含传统碱基的寡聚物相比，具有增强的形成双链或三链的能力。该寡聚物包含5-（1-丙炔基）尿嘧啶，5-（1-丙炔基）胞嘧啶或相关类似物的碱基。本发明的寡聚物能够（i）通过在生理pH值下与靶DNA双链的主沟结合，形成与各种靶序列（如病毒或癌基因序列）的三链，或（ii）通过结合单链DNA或靶基因编码的RNA而形成双链。本发明的寡聚物可以被纳入药学可接受的载体中，并且可以构建任何所需的序列，只要序列通常包括一个或多个被本发明类似物替换的碱基。本发明的组合物可以用作制药剂治疗各种由病毒引起的疾病，并可用于诊断目的，以检测病毒或疾病情况。
• ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES
  申请人：——

  公开号：US20040265802A9

  公开（公告）日：2004-12-30

  Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.

  本发明披露了一种新型寡聚物，与仅含传统碱基的寡聚物相比，其具有增强的双链或三链形成能力。该寡聚物包含碱基5-(1-丙炔基)尿嘧啶，5-(1-丙炔基)胞嘧啶或相关类似物。本发明的寡聚物能够(i)在生理pH下通过耦合到目标DNA双链的主沟槽形成三链，如病毒或癌基因序列，或(ii)通过结合到单链DNA或由目标基因编码的RNA形成双链。本发明的寡聚物可以被纳入到药学可接受的载体中，并且可以构建任何所需的序列，只要该序列通常包括一个或多个被本发明的类似物替换的碱基。本发明的组合物可以用作制药剂治疗各种疾病，如由病毒引起的疾病，并且可以用于诊断目的，以检测病毒或疾病情况。
• Method and reagents for in vitro oligonucleotide synthesis
  申请人：GENENTECH, INC.

  公开号：EP0219342A2

  公开（公告）日：1987-04-22

  A method is provided for the high fidelity. rapid and economical in vitro synthesis of oligonucleotides. Nucleoside H-phosphonates are condensed in seriatim using a dehydrating agent to produce a poly (nucleoside H-phosphonate). The product is oxidized to yield the desired oligonucleotide. A novel reagent is provided for multiple nucleoside additions in single cycles.

  提供了一种高保真、快速和经济的体外合成寡核苷酸的方法。使用脱水剂将核苷 H-膦酸盐依次缩合，生成聚（核苷 H-膦酸盐）。该产物经氧化后可得到所需的寡核苷酸。本发明提供了一种新型试剂，可在单个循环中添加多个核苷。